A Phase IIa study of Alto Neuroscience’s ALTO-100 has demonstrated clear evidence of efficacy and a favourable safety record in patients with major depressive disorder (MDD). In the study, patients with a biomarker profile that ties back to a mechanistic understanding of ALTO-100 and depression exhibited a significantly greater change in Montgomery-Åsberg Depression Rating Scale […]
